Gsa Capital Partners LLP Synthetic Biologics, Inc. Transaction History

Gsa Capital Partners LLP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.5 $743,148 - $1.24 Million	-275,240 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.3 - $5.8 $1.18 Million - $1.6 Million	275,240 New	275,240 $126,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.